

# ToxTwin V2.3 – User Guide

---

Twingital Institute · April 2026 · Version 2.3

---

**Regulatory disclaimer.** ToxTwin is a computational decision-support tool. Its predictions do not replace the in vitro and in vivo tests required under ICH S2(R1), S7A and S7B guidelines. They do not constitute a regulatory opinion.

---

## Table of Contents

1. [What is ToxTwin?](#)
  2. [How to submit a molecule](#)
  3. [The 14 endpoints – what they mean](#)
  4. [Reading and interpreting results](#)
  5. [Applicability domain – when to trust the model](#)
  6. [The Phi-4 interpretation – what it is and what it is not](#)
  7. [Limitations and appropriate use cases](#)
  8. [Frequently asked questions](#)
- 

## 1. What is ToxTwin?

ToxTwin is a toxicological prediction model that analyses the chemical structure of a molecule to estimate its probability of activity across 14 regulatory biological endpoints. It uses a graph neural network (GNN) trained on high-throughput screening data from the ChEMBL and Tox21 databases.

**What ToxTwin does:** - Estimate the preliminary toxicological risk of a molecule from its structure alone - Cover 12 Tox21 endpoints (nuclear receptors and cellular stress response) as well as hERG channel inhibition and Ames mutagenicity - Signal whether the molecule falls within the model's applicability domain - Generate a synthetic pharmacological interpretation

**What ToxTwin does not do:** - Replace mandatory biological tests (ICH S2, S7B) - Predict in vivo toxicity, pharmacokinetics or drug interactions - Provide a legally binding regulatory opinion - Guarantee an exhaustive toxicological profile for a drug candidate

## V2.3 performance (5-fold scaffold CV strict):

| Endpoint group       | Mean AUC      | Protocol           |
|----------------------|---------------|--------------------|
| Tox21 (12 endpoints) | 0.867 ± 0.043 | 5-fold scaffold CV |
| Ames mutagenicity    | 0.843 ± 0.029 | 5-fold scaffold CV |
| hERG inhibition      | 0.785 ± 0.053 | 5-fold scaffold CV |

## 2. How to submit a molecule

### 2.1 Preparing the SMILES notation

ToxTwin accepts molecules in **SMILES notation** (Simplified Molecular Input Line Entry System) — the standard textual representation of chemical structure.

#### What is a SMILES?

A SMILES is a string of characters that describes the connectivity of a molecule.  
Examples:

| Molecule    | SMILES                                  |
|-------------|---|
| Aspirin     | <chem>CC(=O)Oc1ccccc1C(=O)O</chem>      |
| Ibuprofen   | <chem>CC(C)Cc1ccc(cc1)C(C)C(=O)O</chem> |
| Caffeine    | <chem>Cn1cnc2c1c(=O)n(c(=O)n2C)C</chem> |
| Paracetamol | <chem>CC(=O)Nc1ccc(O)cc1</chem>         |

#### How to obtain a SMILES for your molecule:

- **PubChem** (free): search at [pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov) — the canonical SMILES is displayed in the compound record
- **ChEMBL** (free): [ebi.ac.uk/chembl](https://ebi.ac.uk/chembl)
- **ChemDraw / MarvinSketch**: draw the structure → Copy → SMILES
- **RDKit** (Python): `Chem.MolToSmiles(mol)`

**Tip.** Always use the canonical SMILES rather than isomeric or arbitrary SMILES. ToxTwin applies RDKit canonicalisation upstream, but starting from a canonical SMILES reduces the risk of representation artefacts.

## 2.2 Demo interface

1. Open [twingital-ventures.com/en/achievements/toxtwin-demo/](https://twingital-ventures.com/en/achievements/toxtwin-demo/)
2. Paste your SMILES into the input field, or click a quick example (Aspirin, Ibuprofen, Caffeine, Pyrene)
3. Enter the molecule name (optional — for report readability)
4. Click **Analyse molecule** or press `Ctrl+Enter`
5. Wait for results (10–20 seconds depending on server load)

**Freemium quota:** 3 free analyses per visitor. Free registration unlocks 5 additional analyses. Professional API access available on request.

## 2.3 Valid and invalid SMILES

| Situation                               | Behaviour                                    |
|---|--|
| Valid SMILES, known molecule            | Full prediction                              |
| Valid SMILES, out-of-domain molecule    | Prediction with applicability domain warning |
| Invalid SMILES (syntax error)           | Error message — verify with RDKit or PubChem |
| Very large molecule (> 500 heavy atoms) | Not recommended — likely out of domain       |
| Mixture or salt ( . in SMILES)          | Largest fragment processed only              |

## 3. The 14 endpoints — what they mean

### 3.1 Nuclear Receptors (7 endpoints)

These endpoints assess a molecule's ability to activate or inhibit nuclear receptors — regulatory proteins involved in gene expression and endocrine disruption.

| Endpoint            | Receptor                           | Toxicological implication                                |
|---------------------|------------------------------------|--|
| <b>NR-AR</b>        | Androgen receptor (full)           | Androgenic endocrine disruption · developmental risk     |
| <b>NR-AR-LBD</b>    | Androgen receptor (LBD domain)     | Structural specificity of the binding site               |
| <b>NR-AhR</b>       | Aryl hydrocarbon receptor          | CYP1A1/1A2 induction · indirect genotoxicity             |
| <b>NR-Aromatase</b> | Aromatase (CYP19A1)                | Inhibition of oestrogen synthesis · endocrine disruption |
| <b>NR-ER</b>        | Oestrogen receptor $\alpha$ (full) | Oestrogenic activity · hormonal risk                     |

| Endpoint                           | Receptor                                 | Toxicological implication                    |
|------------------------------------|--|--|
| <b>NR-ER-LBD</b>                   | Oestrogen receptor $\alpha$ (LBD domain) | Structural specificity of the binding site   |
| <b>NR-PPAR-<math>\gamma</math></b> | PPAR-gamma                               | Lipid metabolism · adipocyte differentiation |

### 3.2 Cellular Stress Response (5 endpoints)

These endpoints assess a molecule's ability to trigger cellular stress pathways — indicators of genomic, mitochondrial or protein toxicity.

| Endpoint        | Pathway                          | Toxicological implication   |
|-----------------|----------------------------------|---|
| <b>SR-ARE</b>   | Nrf2-ARE (oxidative stress)      | Electrophilicity · oxidative stress · antioxidant defence induction |
| <b>SR-ATAD5</b> | DNA replication (ATAD5)          | Genomic instability · replication perturbation                      |
| <b>SR-HSE</b>   | Heat shock response (HSP70)      | Protein stress · denaturation · misfolding                          |
| <b>SR-MMP</b>   | Mitochondrial membrane potential | Mitochondrial dysfunction · cytotoxicity                            |
| <b>SR-p53</b>   | p53 pathway (genome guardian)    | DNA damage · priority genotoxic signal                              |

### 3.3 Pharmacotoxicology (2 endpoints)

| Endpoint    | Target                         | Regulatory reference   |
|-------------|--------------------------------|--|
| <b>hERG</b> | Potassium channel KCNH2 (hERG) | ICH S7B · responsible for > 30% of post-approval withdrawals |
| <b>Ames</b> | Salmonella mutagenicity        | ICH S2(R1) · first mandatory genotoxicity test               |

**Note on hERG and Ames.** These two endpoints have measured performance below the regulatory target in V2.3 (AUC 0.785 and 0.843 respectively). Their predictions are indicative and must be confirmed by the corresponding regulatory tests before any development decision.

## 4. Reading and interpreting results

### 4.1 Probability scores

Each endpoint returns a score between 0 and 1 representing the **calibrated probability** that the molecule is active on that endpoint.

| Score       | Risk level      | Interpretation   |
|-------------|-----------------|--|
| < 0.25      | <b>Low</b>      | Non-significant signal in the model's context            |
| 0.25 - 0.50 | <b>Moderate</b> | Signal to monitor — additional investigation recommended |
| 0.50 - 0.75 | <b>High</b>     | Concerning signal — experimental investigation priority  |
| > 0.75      | <b>Critical</b> | Strong signal — mandatory experimental investigation     |

**Important:** these thresholds are indicative and must be contextualised relative to the molecule's structural profile, therapeutic class, and the overall toxicological profile.

### 4.2 Reading a complete profile

A complete toxicological profile is read at three levels:

**1. Dominant signals** — endpoints with score > 0.25. These are the priority points of attention. A high SR-p53 signal combined with a moderate SR-ARE signal suggests a coherent potential genotoxic activity (electrophilic reactivity, DNA damage, oxidative stress).

**2. Structural coherence** — signals should be consistent with the molecule's functional groups. A high hERG signal is expected for lipophilic molecules bearing a basic nitrogen. An NR-AhR signal is expected for planar aromatic compounds.

**3. Applicability domain context** — a high score on an out-of-domain molecule should be interpreted with increased caution (see section 5).

### 4.3 Interpretation example — Aspirin

**SMILES:** CC(=O)Oc1ccccc1C(=O)O

| Endpoint | V2.3 Score | Level |
|----------|------------|-------|
| NR-ER    | 0.031      | Low   |
| SR-ARE   | 0.008      | Low   |
| hERG     | 0.093      | Low   |
| Ames     | 0.029      | Low   |

| Endpoint   | V2.3 Score | Level |
|------------|------------|-------|
| All others | < 0.015    | Low   |

**Applicability domain:** IN (Tanimoto 0.857 — molecule well represented in the training corpus)

**Reading:** Low risk profile across all 14 endpoints, consistent with Aspirin's well-documented pharmacological profile. The hERG signal (0.093) remains below the moderate concern threshold. The prediction is reliable (molecule within the applicability domain).

## 5. Applicability domain — when to trust the model

### 5.1 Definition

The **applicability domain** (AD) indicates whether the submitted molecule is structurally similar to molecules on which the model was trained. Outside this domain, predictions are **extrapolations** — potentially less reliable.

ToxTwin uses a composite AD score based on three signals:

| Signal                       | Weight | What it measures  |
|------------------------------|--------|---|
| Tanimoto similarity          | 30%    | Structural proximity to the nearest training corpus neighbour |
| k-NN distance (latent space) | 40%    | Distance in the learned representation space                  |
| KDE density                  | 30%    | Local density of the training corpus around the molecule      |

### 5.2 Interpreting the applicability domain badge

| Badge                                 | Meaning                | Recommendation  |
|---------------------------------------|------------------------|---|
| ✓ <b>In applicability domain</b>      | Composite score > 0.40 | Reliable prediction within the model's limits                 |
| ⚠ <b>Outside applicability domain</b> | Composite score ≤ 0.40 | Indicative prediction only — experimental validation priority |

### 5.3 Common causes of out-of-domain results

- **Novel scaffolds** with no structural precedent in ChEMBL or Tox21

- **Unusual functional groups:** transition metals, charged halogens, highly strained rings
- **Peptides and oligonucleotides:** outside the model's scope (trained on small drug-like molecules)
- **Polymers and macromolecules**
- **Organometallic compounds**

An out-of-domain score does not mean the molecule is toxic — it means the model has insufficient data to produce a reliable prediction.

---

## 6. The Phi-4 interpretation — what it is and what it is not

Each analysis is accompanied by a **textual interpretation** generated by Phi-4 14B, a scientific language model running locally on the Twingital Institute infrastructure.

### What the interpretation provides

- Narrative synthesis of the most significant signals
- Correlation with the molecule's functional groups
- Overall risk level assessment (Low / Moderate / High / Critical)
- Regulatory context of the endpoints concerned

### What the interpretation does not provide

- A regulatory opinion
- An in vivo prediction
- A guarantee of toxicological completeness
- A substitute for the judgement of a qualified toxicologist

The interpretation is a starting point for reflection, not a conclusion. It must be reviewed and validated by a toxicology expert before any development decision.

---

## 7. Limitations and appropriate use cases

### 7.1 Appropriate use cases ✓

- **Early triage** of a compound library (computational screening before biological testing)

- **Mechanistic hypotheses** on the potential toxicity profile of a structure
- **Prioritisation** of endpoints to test first when designing experiments
- **Training and education** on structure-activity relationships in toxicology
- **Comparative monitoring** between structural analogues

## 7.2 Inappropriate use cases *X*

- **Regulatory decision** without experimental confirmation (ICH S2, S7B)
- **Substitute for the preclinical dossier** in a marketing authorisation application
- **Prediction for out-of-scope classes:** biologics, oligonucleotides, peptides > 50 amino acids
- **Assessment of mixtures or degradation products** without a valid individual SMILES

## 7.3 Endpoints not currently covered

ToxTwin V2.3 does not cover (planned for V3.0 and beyond):

- DILI (Drug-Induced Liver Injury)
- ClinTox (general clinical toxicity)
- Extended structural cardiotoxicity (hERG only currently)
- Phototoxicity
- Reproductive toxicity (DART)
- Metal complexes and organometallic compounds

## 8. Frequently asked questions

### **Q: My SMILES generates an "invalid" error. What should I do?**

Verify the SMILES on PubChem or using the online tool [cheminfo.org](http://cheminfo.org). The most common errors: unclosed parentheses, incorrect charges, unsupported atoms.

### **Q: The hERG score is high for my molecule. Should I abandon it?**

No. A high score is a warning signal that justifies a patch-clamp test (ICH S7B), not a decision to stop development. Many approved drugs show moderate hERG scores without clinical QT interval prolongation.

### **Q: My molecule is outside the applicability domain. Are the scores useless?**

No — they remain indicative. A strong signal (> 0.5) on a major endpoint warrants investigation even outside the domain. However, a weak signal outside the domain cannot be interpreted as an absence of toxicity.

### **Q: Do scores change between two identical submissions?**

No. Inference is deterministic (dropout disabled in evaluation mode). Identical SMILES always produce identical scores.

**Q: Can I submit a SMILES with defined stereochemistry?**

Yes. ToxTwin takes stereochemistry into account in the molecular featurisation. Enantiomers may produce different scores if their biological profiles differ.

**Q: How do I access the API to integrate ToxTwin into my pipeline?**

Via the [contact form](#). The REST API exposes the `/v1/score-toxicity` and `/v1/interpret` endpoints. Full technical documentation is available on request.

**Q: Are submitted SMILES stored?**

No. SMILES are used solely for real-time inference and are not recorded in our databases.

---

*ToxTwin V2.3 · Twingital Institute / Qualees · April 2026*

*This document does not constitute a regulatory opinion. ToxTwin is a computational decision-support tool intended for pharmaceutical research and toxicology professionals.*